Literature DB >> 2802738

[Forms of treatment and results in invasive vulvar cancer].

M Lahousen1.   

Abstract

Between 1970 and 1982, 113 patients were treated for invasive vulvar cancer in FIGO stages I-IV; 97 patients were available for follow-up. Forty-one patients (42.3%) underwent radical vulvectomy and lymphadenectomy, 21 underwent simple vulvectomy, and 12 (12.4%) had electric resection of the lesion; 42 patients (43.3%) received postoperative radiotherapy. The 5-year survival rate was 61.8% after surgery and radiotherapy. Five-year survival in stages I, II, and III was 85.3%, 60.7%, and 17.9%, respectively. Overall 5-year survival was 52.6%. Patients with small, highly differentiated squamous cell cancers, without lymph node involvement, did best.

Entities:  

Mesh:

Year:  1989        PMID: 2802738     DOI: 10.1007/bf02417402

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

1.  The anatomy of the lymphatic drainage of the vulva and its influence on the radical operation for carcinoma.

Authors:  S WAY
Journal:  Ann R Coll Surg Engl       Date:  1948-10       Impact factor: 1.891

2.  [Vulvar cancer].

Authors:  B U Sevin; H D Homesley
Journal:  Gynakologe       Date:  1986-06

3.  [Vulvar carcinoma. Report from the years 1952 to 1965].

Authors:  K Weghaupt
Journal:  Geburtshilfe Frauenheilkd       Date:  1971-12       Impact factor: 2.915

4.  [Treatment of vulvar cancer based on stage].

Authors:  W E Lucas
Journal:  Gynakologe       Date:  1981-09

5.  Management of regional lymph nodes and their prognostic influence in vulvar cancer.

Authors:  N F Hacker; J S Berek; L D Lagasse; R S Leuchter; J G Moore
Journal:  Obstet Gynecol       Date:  1983-04       Impact factor: 7.661

6.  [Radiotherapy of vulvar cancer. Treatment results of electron therapy in 446 patients 1956 to 1978].

Authors:  H J Frischbier; K Thomsen; H J Schmermund; F Oberheuser; G Höhne; H U Lohbeck
Journal:  Geburtshilfe Frauenheilkd       Date:  1985-01       Impact factor: 2.915

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.